Analysis of the responsible genome by the next generation sequencing (NGS) for drug sensitivity and prediction of prognosis in patients with newly diagnosed untreated multiple myeloma

Analysis of the responsible genome by the next generation sequencing (NGS) for drug sensitivity and prediction of prognosis in patients with newly diagnosed untreated multiple myeloma - Gene analysis using NGS of patients with newly diagnosed untreated multiple myeloma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025835

Enrollment

150

Registered

2017-02-01

Start date

2017-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Previously untreated multiple myeloma patients diagnosed according to criteria of IMW conference report for 2014 and who are eligible for systemic treatment. 2.Provide who has written informed consent

Exclusion criteria

Exclusion criteria: 1. 19 years or younger 2. Patients identified as ineligible by the directors and co-working of each institute.

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS) in each of the baseline genomic subgroup of at diagnosis.	—

Secondary

Measure	Time frame
Correlation of PFS and quantity of tumor element evaluated three months after the start of therapy Correlation of PFS and quantity of tumor element evaluated six months after the start of therapy Correlation of TNT and quantity of tumor element evaluated three months after the start of therapy Correlation of TNT and quantity of tumor element evaluated six months after the start of therapy Genetic mutations of myeloma cells associated with treatment	—

Measure

Time frame

Correlation of PFS and quantity of tumor element evaluated three months after the start of therapy Correlation of PFS and quantity of tumor element evaluated six months after the start of therapy Correlation of TNT and quantity of tumor element evaluated three months after the start of therapy Correlation of TNT and quantity of tumor element evaluated six months after the start of therapy Genetic mutations of myeloma cells associated with treatment

—

Countries

Japan

Contacts

Public ContactYoshikazu Kamiya

National Hospital Organization, Higashi Nagoya National Hospital Division of Hematology and Medical Oncology

yskzkmy@e-nagoya.hosp.go.jp+81-52-801-1151

Outcome results